Topics

Lilly's Q1: 2 Pipeline Drugs Dropped, Patents and Pricing Pressures

20:00 EDT 29 Apr 2019 | BioSpace

The company indicated it was dropping LY2606368, prexasertib, a CHK1 drug in Phase II, and LY3023414, a PI3k/mTOR inhibitor that was also in Phase II. Both drugs were highlighted in 2017 as moving forward for the company’s oncology pipeline.

Original Article: Lilly's Q1: 2 Pipeline Drugs Dropped, Patents and Pricing Pressures

NEXT ARTICLE

More From BioPortfolio on "Lilly's Q1: 2 Pipeline Drugs Dropped, Patents and Pricing Pressures"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...